SV, Sofinnova in $30m series-A for Sitryx

GlaxoSmithKline and Longwood Fund also took part in the round, which will fund research and development.

SV was a founding investor in Sitryx, and has supported it in its recruitment of senior research and management teams, led by former UCB Pharma senior vice-president of discovery Neil Weir as CEO.

Company
Founded in 2018, London-headquartered Sitryx is a biotech company focusing on immuno-oncology and immuno-inflammation for the treatment and prevention of a range of cancer and autoimmune conditions.

People
SV Health Investors – Houman Ashrafian (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Sofinnova Partners
• Venture